Cholesteryl phenylacetate

<strong>Cholesteryl phenylacetate</strong>_x000D_ <strong>Catalog number:</strong> B2018035_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 10 g_x000D_ <strong>Molecular Weight or Concentration:</strong> 504.79_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> a molecular tool for various biochemical applications_x000D_ <strong>Storage:</strong> -20℃_x000D_ <strong>Keywords:</strong> 3β-Hydroxy-5-cholestene 3-phenylacetate, 5-Cholesten-3β-ol 3-phenylacetate_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Cohen MP, Shea EA, Wu VY. Inhibiting low-density lipoprotein glycation ameliorates increased cholesteryl ester synthesis in macrophages and hypercholesterolemia and aortic lipid peroxidation in streptozotocin diabetic rats Metabolism. 2010 May;59(5):658-63._x000D_ 2: Botta E, Meroño T, Saucedo C, Martín M, Tetzlaff W, Sorroche P, Boero L, Malah V, Menafra M, Gómez Rosso L, Chapman JM, Kontush A, Soriano E, Brites F. Associations between disease activity, markers of HDL functionality and arterial stiffness in patients with rheumatoid arthritis Atherosclerosis. 2016 Aug;251:438-444._x000D_ 3: Meroño T, Gómez L, Sorroche P, Boero L, Arbelbide J, Brites F. High risk of cardiovascular disease in iron overload patients Eur J Clin Invest. 2011 May;41(5):479-86._x000D_ 4: Groot PH, Pearce NJ, Yates JW, Stocker C, Sauermelch C, Doe CP, Willette RN, Olzinski A, Peters T, d'Epagnier D, Morasco KO, Krawiec JA, Webb CL, Aravindhan K, Jucker B, Burgert M, Ma C, Marino JP, Collins JL, Macphee CH, Thompson SK, Jaye M. Synthetic LXR agonists increase LDL in CETP species J Lipid Res. 2005 Oct;46(10):2182-91._x000D_ 5: Gaur PK, Purohit S, Kumar Y, Mishra S, Bhandari A. Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation Drug Dev Ind Pharm. 2014 Apr;40(4):568-76._x000D_ 6: Gaur PK, Purohit S, Kumar Y, Mishra S, Bhandari A. Preparation, characterization and permeation studies of a nanovesicular system containing diclofenac for transdermal delivery Pharm Dev Technol. 2014 Feb;19(1):48-54._x000D_ 7: Berstein G, Haga T, Ichiyama A. Effect of the lipid environment on the differential affinity of purified cerebral and atrial muscarinic acetylcholine receptors for pirenzepine Mol Pharmacol. 1989 Oct;36(4):601-7._x000D_ 8: Gaur PK, Purohit S, Mishra S. Development of aceclofenac nanovesicular system using biomaterial for transdermal delivery: physical characterization, ex vivo, in vivo, and anti-inflammatory studies J Biomater Sci Polym Ed. 2013;24(18):2126-41._x000D_ 9: Fedorova EV, Fok EM, Bakhteeva VT, Lavrova EA, Parnova RG. [Deposition of exogenous and endogenously generated unsaturated fatty acids in lipid droplets triacylglycerol as a mechanism of its sequestration in epithelial cells] Ross Fiziol Zh Im I M Sechenova. 2014 Aug;100(8):964-78._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/2151550">10: Pill J, Wolf O, Schmelz A, Stegmeier K, Metz J. Investigations of the antiatherosclerotic effect of the thromboxane A2 receptor antagonist Daltroban Z Kardiol. 1990;79 Suppl 3:155-60.</a>_x000D_ _x000D_ <strong>Products Related to Cholesteryl phenylacetate can be found at</strong> <a href="https://moleculardepot.com/product-category/Chemicals /"> Chemicals </a>